To investigate the clinical efficacy of intravenous carbazochrome sodium sulfonate (CSS) ,an oxidation substance of adrenaline,in improving visual clarity (VC), perioperative haemostasis, and anti-inflammatory effects during arthroscopic rotator cuff repair. This was a Single-Center,Single-Surgeon,Randomised Controlled, Triple-Blinded, Prospective Study,From August 2023 and August 2024,195 patients Undergoing Arthroscopic Rotator Cuff Repair were enrolled and randomly assigned to 3 groups: Group A received an intravenous infusion of CSS; Group B received an intravenous infusion of tranexamic acid (TXA); and Group C received an intravenous infusion of 0.9% sodium chloride.Patients with massive rotator cuff tear,frozen shoulder,hypertension,severe liver/renal dysfunction,long-term use of anticoagulants or antiplatelet drugs,bleeding disorders or severe cardiopulmonary diseases were excluded.After each surgery,a trained and independent evaluator assessed the clarity of images based on Visual Clarity Scale (VCS),and all related clinically Outcomes were recorded.The primary outcome was arthroscopic VC,The secondary outcomes were operative duration, irrigation fluid volume, discarded irrigation fluid red blood cell count, intraoperative mean blood pressure, inflammatory marker levels, haemoglobin levels, Visual Analog Scale pain scores, and shoulder joint enlargement rate. 195 patients were enrolled in total,and they were randomised into three groups:Group A(65 patients:21 male, 44 female; mean age=56.4 years),Group B(65 patients:29 male, 36 female; mean age=57.0 years),Group C(65 patients:24 male, 41 female; mean age=56.7 years)VC scale scores were not significantly different during an arthroscopic examination(5(4,5) vs 5(4,5) vs 5(4,5) , p=0.859),but Group A had higher scores than Groups B and C during subacromial(5(5,5) vs 4(3,4) vs 3(2,3.5),P <0.001) and rotator cuff repair(5(5,5) vs 4(3,4) vs 3(3,4),P <0.001). Group A showed significant advantages over Groups B and C in operative duration(50.4±8.0 min vs 66.4±13.7 min vs 70.2±17.4 min,P <0.001), intraoperative infusion volume(11338.5±1381.0ml vs 18483.1±1808.7ml vs 19047.7±1984.1ml,P <0.001), postoperative shoulder joint enlargement rate(8.2(3.0,11.7)% vs 14.1(9.2,18.1)% vs 15.4(13.8,16.3)%,P <0.001),and discarded infusion red blood cell count(12.6±2.3*109/L vs 19.6±2.0*109/L vs 20.4±2.2*109/L,P <0.001). On postoperative days (PODs) 1, 2, and 3, haemoglobin levels were significantly lower in Group C than in Groups A and B. Inflammatory marker levels on PODs 1, 2, and 3 were not significantly different between Groups A and B (P > 0.05) but were significantly lower than those in Group C (P < 0.05). A total of 157 patients (80.51% of the overall cohort) showed a change in Visual Analog Scale pain (VAS) scores that met the MCID threshold three days after surgery.VAS scores on PODs 1, 2, and 3 were lower in Group A than in Groups B and C (P < 0.05). No adverse drug reactions or surgical complications occurred in any patients. CSS can effectively improve VC, reduce perioperative blood loss, decrease the inflammatory response, alleviate early postoperative pain and shoulder joint swelling, and does not increase the incidence of adverse reactions and complications.
Read full abstract